Showing 801 - 820 results of 112,027 for search '(( 50 ((a decrease) OR (nn decrease)) ) OR ( 5 ((a decrease) OR (nn decrease)) ))', query time: 1.65s Refine Results
  1. 801

    Decrease of locomotor activity in <i>Auts2</i> mutant mice during habituation. by Kei Hori (840871)

    Published 2016
    “…<p>(A) Spontaneous locomotor activity for habituation to the novel environment was measured every 5 min for 60 min. …”
  2. 802
  3. 803
  4. 804
  5. 805
  6. 806
  7. 807

    MAP-2 decrease follows the early PSA-NCAM reduction induced by glutamate exposure. by María Fernanda Podestá (639243)

    Published 2014
    “…(A) Microphotographs of hippocampal neurons in culture doubled stained for MAP-2 and PSA-NCAM. …”
  8. 808

    To be funny or not to be funny: Gender differences in student perceptions of instructor humor in college science courses by Katelyn M. Cooper (5634851)

    Published 2018
    “…<div><p>For over 50 years instructor humor has been recognized as a way to positively impact student cognitive and affective learning. …”
  9. 809
  10. 810
  11. 811
  12. 812
  13. 813
  14. 814
  15. 815

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    “…<i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC<sub>50</sub> = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC<sub>50</sub> = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC<sub>50</sub> = 2.29 ± 0.92 μM (MCF-7)]. …”
  16. 816

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    “…<i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC<sub>50</sub> = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC<sub>50</sub> = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC<sub>50</sub> = 2.29 ± 0.92 μM (MCF-7)]. …”
  17. 817
  18. 818
  19. 819

    A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity by Regina Michelis (2889092)

    Published 2019
    “…In patients with abnormal C5, basal levels of sC5b-9 and C5a were increased while activities of the CP and of the CP C5-convertase, the immediate C5-upstream complex, were decreased compared to NC and to patients with normal C5. …”
  20. 820